Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 494.00K | 672.00K | 200.00K | 131.00K | 375.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 494.00K | 672.00K | 200.00K | 131.00K | 375.00K |
| Cost of Revenue | 4.86M | 5.55M | 7.45M | 7.43M | 8.35M |
| Gross Profit | -4.36M | -4.88M | -7.25M | -7.30M | -7.98M |
| SG&A Expenses | 6.54M | 8.62M | 7.07M | 7.48M | 9.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.39M | 14.18M | 14.52M | 14.91M | 17.69M |
| Operating Income | -10.90M | -13.50M | -14.32M | -14.78M | -17.31M |
| Income Before Tax | -3.07M | 851.00K | -26.83M | -15.38M | -19.34M |
| Income Tax Expenses | -- | -537.00K | -- | -- | -- |
| Earnings from Continuing Operations | -3.07M | 1.39M | -26.83M | -15.38M | -19.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.07M | 1.39M | -26.83M | -15.38M | -19.34M |
| EBIT | -10.90M | -13.50M | -14.32M | -14.78M | -17.31M |
| EBITDA | -10.13M | -12.78M | -13.87M | -14.33M | -16.88M |
| EPS Basic | 0.00 | 0.00 | -0.02 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | -0.02 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.58B | 1.54B | 1.49B | 1.44B | 1.36B |
| Average Diluted Shares Outstanding | 1.58B | 1.54B | 1.49B | 1.44B | 1.36B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |